RxDoctor Payments Data

Khalid Sheikh, MD

Cardiovascular Disease · Melbourne, FLNPI 1639278427

Payments from drug & device makers

$335,270in general payments, 2019–2025

Across 389 payments — averaging $861.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$126K
  • Esperion Therapeutics, Inc.$105K
  • Amarin Pharma, Inc.$102K
  • Boehringer Ingelheim$2K
  • Novartis$176
  • Cvrx, Inc.$148
  • plus $550 from 10 others

What the payments were for

  • Consulting fees$9850%
  • Speaking & faculty fees$246,11488%
  • Travel & lodging$25,9699%
  • Food & beverage$7,4883%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$335,270 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$201,274
Medicare patients
1,717
Services billed
4,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$299,670
XareltoRivaroxaban145$150,933
EntrestoSacubitril/Valsartan50$54,033
Praluent PenAlirocumab41$32,167
Repatha SureclickEvolocumab44$30,837
MultaqDronedarone Hcl21$30,094
Dabigatran EtexilateDabigatran Etexilate Mesylate76$27,318
JardianceEmpagliflozin14$23,528
VascepaIcosapent Ethyl16$14,861
NexlizetBempedoic Acid/Ezetimibe17$14,123
Rosuvastatin Calcium416$9,363
Ezetimibe168$6,952
Metoprolol Succinate295$6,880
Atorvastatin Calcium369$5,666
Losartan Potassium288$5,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$299,670291 claims
Johnson & JohnsonXarelto$141$150,933145 claims
NovartisEntresto$176$54,03350 claims
Sanofi-aventis U.S. LLCMultaq$35$30,09421 claims
Boehringer IngelheimJardiance$2,055$23,52814 claims
Esperion Therapeutics, Inc.Nexlizet$104,900$14,12317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →